Cholesterol

A prespecified analysis found the PCSK9 inhibitor reduced total events 20% in high-risk patients with no prior heart attack or stroke.

From enlicitide to Lp(a)-lowering siRNAs, a look at the add-on therapies helping high-risk patients reach stricter LDL targets below 55 mg/dL.

Older triglyceride drugs manage only 10% to 30% reductions; newer injectables go far further, with FCS as their first key role.

Jeremy Johnson, PharmD, on how oral and injectable proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are helping high-risk patients hit LDL targets statins alone can't reach.

The agency's decision pairs a new self-administration device with label language tying LDL-C lowering to cardiovascular outcomes.

A new machine learning version of the Martin-Hopkins equation matches the original's accuracy while making implementation easier for laboratories.

Seth Martin, MD, MHS, discusses a simplified machine-learning equation that helps labs deliver more accurate LDL-C results at no cost.

SHASTA-3 and SHASTA-4 also showed a statistically significant drop in acute pancreatitis events, supporting a planned US sNDA this year.

The 20-mg once-daily tablet is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C).

A simplified, no-cost machine learning version of the Martin-Hopkins equation matched the original's accuracy across millions of blood samples, helping clinicians identify patients who qualify for lipid-lowering therapy.

Cheeley maps out the resources—courses, certifications, communities, and a retail pharmacy call to action—that can take any pharmacist deeper into lipid management.

Cheeley takes listeners inside her clinical decision-making process—from statin intolerance to PCSK9 inhibitors to omega-3s—and explains why patient buy-in is as important as the prescription itself.

TIMI Study Group investigators presented new VESALIUS-CV data showing that intensive LDL-C lowering with evolocumab reduces major cardiovascular events, reinforcing the "lower is better, earlier is better" approach to lipid management.

Correcting the misinformation around statins and cardiovascular disease, and reframing Lp(a) as a genetic condition, not a personal failure, can be a powerful clinical tool.

The landscape of cardiovascular prevention is shifting from a focus on surrogate biomarkers to a more granular, image-based assessment of actual disease burden.

From prior authorization barriers to population health gaps, Cheeley explains why adherence — not initiation — is where pharmacists can make their biggest impact.

New 2026 lipid guidelines push earlier screening, PREVENT risk scoring, and tougher LDL/ApoB targets with expanded nonstatin options.

Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA, highlights key data and events at the 2026 NLA Scientific Sessions.

Joseph Saseen, PharmD, discusses how pharmacists can overcome therapeutic inertia and sequence nonstatin therapies to help patients reach individualized LDL-C goals.

Joseph Saseen, PharmD; and Joel C. Marrs, PharmD, discuss key updates in the 2026 dyslipidemia guidelines and their implications for clinical and pharmacy practice.

2026 dyslipidemia guideline updates highlight earlier risk-based lipid management, expanded biomarker use, and a growing pharmacist role in cardiovascular prevention.

Pharmacists play a central role in shared decision-making by guiding patients through lipid-lowering options, cost considerations, and ongoing monitoring aligned with updated dyslipidemia guidelines.

Real-world data show pharmacist-driven obesity care models may offer greater improvements in hemoglobin A1C and lipid parameters while supporting multidisciplinary, patient-centered care.

Pharmacists can improve statin adherence and refine triglyceride management by leveraging patient-centered counseling, adherence strategies, and updated guideline recommendations prioritizing statins and targeted adjunctive therapies.

Pharmacists play a central role in implementing new dyslipidemia guidelines, including ApoB testing, earlier risk assessment, and expanded use of combination lipid-lowering therapy.